Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07500324

Identification And Validation Of Biomarkers In Ophthalmological Diseases (Age-Related Macular Degeneration, Diabetic Retinopathy And Retinal Detachment) Through Clinical Proteomic Approaches

Led by Fondazione G.B. Bietti, IRCCS · Updated on 2026-06-02

260

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting a prospective interventional translational study to identify and validate protein biomarkers linked to major eye diseases such as age-related macular degeneration, diabetic retinopathy, and retinal detachment. The study aims to improve understanding of these diseases' development and support new diagnostic and prognostic tools in ophthalmology. Approximately 260 participants, including patients with these eye conditions and control subjects without retinal disease, will be enrolled at a single center. Participants will have biological samples collected during routine clinical care, such as peripheral blood, tears, and ocular fluids like aqueous humor, vitreous humor, and subretinal fluid during surgeries. The study involves baseline visits with eye examinations and imaging, followed by additional sample collection during therapeutic procedures when applicable. Advanced proteomics techniques, including high-resolution mass spectrometry, will be used to analyze these samples in phases focusing on biomarker discovery and validation. Throughout the study, participants will undergo comprehensive eye exams, medical history reviews, and non-invasive imaging. Samples will be collected without adding risk beyond routine care. Researchers will examine molecular signatures related to disease onset and progression and assess protein biomarkers over up to 36 months. Data will be statistically analyzed, and all personal information will be protected according to data privacy regulations.

CONDITIONS

Brief Title

Proteomic Biomarker Identification in Age-Related Macular Degeneration, Diabetic Retinopathy and Retinal Detachment

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 65 18 years
  • Ability to understand the study procedures and provide written informed consent
  • Willingness and ability to comply with study procedures and visits
  • Patients with age-related macular degeneration (intermediate or advanced, including geographic atrophy or neovascular AMD)
  • Patients with diabetic retinopathy (non-proliferative or proliferative, with or without diabetic macular edema)
  • Patients undergoing surgery for primary or recurrent retinal detachment
  • Patients scheduled for cataract surgery with no documented retinal diseases
  • Outpatients with no documented retinal diseases
  • For retinal detachment subgroup: patients undergoing macular surgery or cataract surgery with attached retina
Not Eligible

You will not qualify if you...

  • Age < 18 years
  • Presence of infectious ocular diseases
  • Alterations in the electrophoretic profile of gamma globulins

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - 1 day

Participants undergo a baseline evaluation including medical and ophthalmological history, eye examination, non-invasive imaging, and collection of tears and peripheral blood samples.

1 baseline visit (in-person)

Implementation

Duration - Within 1 to 30 days after baseline

Participants undergoing therapeutic procedures have additional biological samples collected during routine clinical care or surgery without additional risk.

1 to 2 visits depending on treatment schedule

Long-term Monitoring

Duration - Up to 36 months

Participants are followed for up to 36 months to identify and validate proteomic biomarkers associated with ophthalmological diseases.

Follow-up visits as part of routine clinical care

Trial Site Locations

Total: 1 location

1

IRCCS Fondazione G.B.Bietti

Roma, Italy, Italy, 00184

Actively Recruiting

Loading map...

Research Team

M

Mariacristina Parravano, MD

T

Tommaso Rossi, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Similar Trials

A Multicenter, Randomized, Double-Masked, Placebo-Controlled...

Age-related Macular Degeneration (AMD)

Actively Recruiting

216 locations

Artificial Intelligence-Aided Screening for Patients With Di...

Age-Related Macular Degeneration (AMD)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here